Climacteric syndrome: novel modalities for menopausal therapy
Prilepskaya V.N. 

V.I. Kulakov Research Center for Obstetrics, Gynecology and Perinatology, Moscow

Climacteric syndrome is a complex of vegetative, vascular, psychic, metabolic, and endocrinological disturbances which significantly reduce the quality of life and require careful treatment selection.
The paper reviews Russian and international published data on clinical manifestations, diagnosis, and treatment of climacteric syndrome. Menopausal hormone therapy (HT) is of special importance. Considering adverse reactions associated with menopausal HT, careful follow-up on drug tolerability as well as complications and side effects is required.
The paper also discusses the results of multicenter double-blind placebo-controlled randomized clinical trials of Pineamin®. The synthesis of polypeptides of pineal gland complex was realized via the development of novel original medicine, Pineamin®. The results of several studies demonstrate that this nontoxic agent rapidly reduces neurological and vegetative signs of climacteric syndrome. Pineamin® can be combined with other methods of menopausal HT. In addition, this agent can be used for other somatic and functional conditions since no negative drug interactions were recognized.
Pineal gland polypeptide complex is a novel treatment modality for climacteric syndrome.

Key words: climacteric syndrome, Pineamin®, menopausal hormone therapy, Pineal gland polypeptide complex.
For citation: Prilepskaya V.N. Climacteric syndrome: novel modalities for menopausal therapy // RMJ. 2017. № 2. P. 105–108.